Disclosure as enclosed

August 07, 2026 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE LTD. National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, “Exchange Plaza”, Plot No. C/1, Dalal Street, G Block, Bandra Kurla Complex, Mumbai - 400 001 Bandra (E), Mumbai – 400 051 SCRIP CODE: 543748 SYMBOL: AARTIPHARM Dear Sir/Madam, Sub: Outcome of Board Meeting Ref: Regulation 30 and 33 of SEBI (LODR) Regulations, 2015 We wish to inform you that the Board of Directors at their meeting held today i.e. Friday, August 07, 2026 inter-alia, considered and approved the following:  The Unaudited Financial Results of the Company (Standalone and Consolidated) for the quarter ended June 30, 2026, on the basis of recommendation of the Audit Committee along with Limited Review Report on the Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026.  The Board of Directors, based on the recommendation of the Nomination and Remuneration Committee, has approved change in designation/role of Shri. Rashesh C. Gogri (DIN: 00066291) from Non-Executive Director to Managing Director of the Company with effect from October 1, 2026, subject to the approval of the shareholders at the ensuing Annual General Meeting.  The Board of Directors, based on the recommendation of the Nomination and Remuneration Committee, has approved the change in designation/role of Smt. Hetal Gogri Gala (DIN: 00005499) from Managing Director to Executive Director of the Company, with effect from October 1, 2026, subject to the approval of the shareholders at the ensuing Annual General Meeting. The disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) read with Part A of Schedule III of the SEBI Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is enclosed herewith as Annexure – A. AARTI PHARMALABS LIMITED www.aartipharmalabs.com I CIN: L24100GJ2019PLC110964 I Email: info@aartipharmalabs.com Admin Office: 204. Udyog Kshelra, 2nd Floor, Mulund -Goregaon Link Road, Mulund (W), Mumbai, PIN -400 080, Maharashtra, INDIA, T: +91 22 679766661 F: +91 22 25653234 Regd. omce: Plot No. 22-C/1 & 22-C/2, 1st Phase, G.1.0.C., Vapi 396195, District-Valsad, Gujarat, !NOIA, T: +91 260 2400467, +91 99099 94655  Approved capacity addition for Development of Intermediate Block at an estimated capex of Rs.149 Crores. The disclosures required under Regulation 30 of the SEBI Listing Regulations read with Part A of Schedule III of the SEBI Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed herewith as Annexure- B.  Reconstitution of Audit Committee and Corporate Social Responsibility (CSR) Committee of the Board of Directors pursuant to applicable provisions of the SEBI Listing Regulations and Companies Act, 2013 with effect from October 1, 2026 as detailed below: Audit Committee Sr Name of Committee Member Designation in Committee 1 Shri Bhavesh Vora Chairman 2 Shri Vinay Nayak Member 3 Shri Vilas Gaikar Member 4 Smt. Jeenal Savla Member 5 Shri. Narendra Salvi Member 6 Shri Rashesh C Gogri Member Corporate Social Responsibility Committee Sr Name of Committee Member Designation in Committee 1 Smt. Hetal Gogri Gala Chairperson 2 Shri Pradeep Thakur Member 3 Smt. Jeenal Savla Member 4 Shri Vilas Gaikar Member  Reconstitution of Stakeholders Relationship Committee of the Board of Directors pursuant to applicable provisions of the SEBI Listing Regulations and the Companies Act, 2013 as under with immediate effect: Stakeholders Relationship Committee Sr Name of Committee Member Designation in Committee 1 Shri Parimal Desai Chairman 2 Shri Narendra Salvi Member 3 Shri Bhavesh Vora Member 4 Shri Rupal Vora Member AARTI PHARMALABS LIMITED www.aartipharmalabs.com I CIN: L24100GJ2019PLC110964 I Email: info@aartipharmalabs.com Admin Office: 204. Udyog Kshelra, 2nd Floor, Mulund -Goregaon Link Road, Mulund (W), Mumbai, PIN -400 080, Maharashtra, INDIA, T: +91 22 679766661 F: +91 22 25653234 Regd. omce: Plot No. 22-C/1 & 22-C/2, 1st Phase, G.1.0.C., Vapi 396195, District-Valsad, Gujarat, !NOIA, T: +91 260 2400467, +91 99099 94655 The meeting of the Board of Directors commenced at 02:00 p.m. and concluded at 06:00 p.m. The above information is also available on the website of the Company: www.aartipharmalabs.com Please take the same on your records. Thanking you, Yours faithfully, For AARTI PHARMALABS LIMITED JEEVAN MONDKAR COMPANY SECRETARY AND LEGAL HEAD ICSI M. NO. A22565 Encl: a/a AARTI PHARMALABS LIMITED www.aartipharmalabs.com I CIN: L24100GJ2019PLC110964 I Email: info@aartipharmalabs.com Admin Office: 204. Udyog Kshelra, 2nd Floor, Mulund -Goregaon Link Road, Mulund (W), Mumbai, PIN -400 080, Maharashtra, INDIA, T: +91 22 679766661 F: +91 22 25653234 Regd, Ottlce: Plot No. 22-C/1 & 22-C/2, 1st Phase, G.1.0.C., Vapi 396195, District-Valsad, Gujarat, !NOIA, T: +91 260 2400467, +91 99099 94655 Annexure – A SR. Particulars Disclosure Shri Rashesh Gogri Smt. Hetal Gogri Gala (DIN: 00066291) (DIN: 00005499) 1 Reason for change viz. appointment, Change in role Change in role re-appointment, resignation, removal, death or otherwise 2 Date of change in Designation October 01, 2026 October 01, 2026 3 Brief profile Not Applicable (since it Not Applicable (since it (In case of Appointment of Director) is change in role) is change in role) 4 Disclosure of relationships between Not Applicable (since it Not Applicable (since it directors (in case of appointment of a is change in role) is change in role) director) However, Shri However, Shri Rashesh Rashesh C. Gogri and C. Gogri and Smt. Hetal Smt. Hetal Gogri Gala Gogri Gala are related to are related to each each other other Annexure – B Sr No. Details Disclosure 1 Existing capacity New Block 2 Existing capacity utilization New Block 3 Proposed capacity addition 405 Kl Period within which the proposed capacity is 4 1 year to be added 5 Investment required Rs. 149 Crores 6 Mode of financing Internal accruals & Borrowings 7 Rationale Capacity expansion to serve intermediate & CDMO customers AARTI PHARMALABS LIMITED www.aartipharmalabs.com I CIN: L24100GJ2019PLC110964 I Email: info@aartipharmalabs.com Admin Office: 204. Udyog Kshelra, 2nd Floor, Mulund -Goregaon Link Road, Mulund (W), Mumbai, PIN -400 080, Maharashtra, INDIA, T: +91 22 679766661 F: +91 22 25653234 Regd. omce: Plot No. 22-C/1 & 22-C/2, 1st Phase, G.1.0.C., Vapi 396195, District-Valsad, Gujarat, !NOIA, T: +91 260 2400467, +91 99099 94655 AARTI PHARMALABS LIMITED STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026 (Amount Rs in Jakhs except EPS) STANDALONE RESULTS Sr. 3 Months Ended Year Ended Particulars No. 30th June 2026 31st March 2026 30th June 2025 31st March 2026 (Unaudited) (Audited) (Unaudited) (Audited) 1 INCOME a) Revenue from Operations (Net) 53,458.78 57,970.05 37,531.06 179,755.17 b) Other Income 293.13 1,053.01 77.13 1,532.32 Total Income 53,751.91 59,023.06 37,608.19 181,287.50 2 EXPENSES a) Cost of Materials Consumed 25,484.09 22,738.30 19,284.86 83,453.22 b) Purchases of Stock-in-Trade 2,444.92 707.35 1,985.44 4,919.11 c) Changes in Inventories of Finished Goods, Work-in-progress and Stock-in-Trade (4,272.20) 4,550.33 (5,294.99) (6,258.22) d) Employee Benefits Expense 4,976.55 4,372.80 4,101.27 17,048.01 e) Finance Costs 1,287.36 1,686.25 679.49 4,690.08 f) Depreciation and Amortisation Expenses 3,002.82 2,815.60 2,275.65 10,429.86 g) Foreign Exchange (Gain)/Loss (346.11) 1,698.83 381.32 3,320.84 h) Other Expenses 11,552.06 12,195.06 7,941.48 39,981.21 Total Expenses 44,129.49 50,764.52 31,354.51 157,584.11 3 Profit/(Loss) before Exceptional Items and Tax (1-2) 9,622.41 8,258.54 6,253.68 23,703.39 4 Exceptional Items - 279.49 5 Profit/(Loss) before Tax (3-4) 9,622.41 8,258.54 6,253.68 23,423.90 6 TAX EXPENSES a) Cur [Showing first 8,000 characters — download PDF for full document]